Alert: Q1 2026 Regulatory & Policy Deep Dive for Psychedelics Merchants

This Q1 2026 briefing provides a comprehensive overview of critical regulatory and policy developments impacting the psychedelics industry. Key updates include FDA actions, progress on various state and federal bills, and advancements in state psychedelics programs, notably 'breaking news' regarding Texas' ibogaine initiative. Merchants should review these multi-jurisdictional insights to proactively navigate evolving compliance landscapes and prepare for anticipated Q2 policy shifts.